Report Highlights

Sternal Closure Systems in the U.S.: Market Overview

The U.S. sternal closure systems market covers stainless steel and titanium sternal wires, rigid plate-and-screw fixation kits, and emerging resorbable devices used after median sternotomy. Market value reached an estimated USD 412 million in 2024, anchored by roughly 200,000 isolated coronary artery bypass grafting procedures and a steady volume of valve operations at American hospitals. Unlike the global market, where Asia Pacific volume growth dominates, U.S. demand rests on procedural acuity and surgeon-level product preference.

Rigid fixation has gained share faster in the U.S. than in Europe because American cardiac surgery cohorts carry higher rates of obesity, diabetes, and osteoporosis, all linked to sternal dehiscence. Sternal wire remains the default closure in most community hospitals, yet academic medical centers increasingly adopt titanium plates after documented mediastinitis costs. DePuy Synthes, KLS Martin, and Zimmer Biomet compete for this clinical niche, and pricing is set at the hospital value analysis committee level rather than by individual surgeons.

Growth Drivers in U.S. Sternal Closure Systems

Demand begins with the aging Medicare population, which accounts for most coronary bypass and valve replacement cases in the United States. The Centers for Disease Control and Prevention reports that roughly 40 percent of American adults have obesity, a comorbidity that raises the probability of deep sternal wound infection and pushes surgeons toward rigid fixation. Transcatheter aortic valve replacement expansion under the 2019 Centers for Medicare and Medicaid Services National Coverage Determination has shifted some valve volume away from open surgery, but total sternotomy volume has held steady.

Hospital quality programs create a second demand driver. The Hospital Readmissions Reduction Program includes coronary artery bypass grafting among targeted conditions, so hospitals that reduce sternal complication readmissions gain penalty relief. The Society of Thoracic Surgeons National Database tracks deep sternal wound infection rates by institution, and public reporting encourages hospitals to purchase fixation systems with documented outcomes. Third, expanding bilateral internal mammary artery harvest in multivessel revascularization increases sternal manipulation and strengthens the clinical case for stronger closure.

Market Restraints and Entry Barriers

Regulatory entry begins with FDA 510(k) clearance, as sternal wires and plate systems are Class II devices reviewed against established predicates. Clearance timelines commonly run four to eight months once a complete submission is accepted, and novel fixation geometries often require mechanical performance testing that lengthens the cycle. Incumbents hold predicate devices that define substantial equivalence, making original designs costly to bring to market and slow to win hospital listing.

Hospital purchasing presents the larger barrier. Value analysis committees in community hospitals require clinical evidence and pricing rebates, while group purchasing organizations including Vizient and Premier negotiate multi-year agreements that bundle sternal closure into cardiac surgery contracts. Because Medicare pays MS-DRG rates that bundle implant costs, hospitals resist premium device pricing. Sunshine Act reporting under Open Payments also restricts surgeon consulting relationships, limiting the informal preference-building that incumbents historically relied on.

Market Opportunities in U.S. Sternal Closure Systems

The most actionable near-term opportunity is rigid titanium fixation for high-risk patients. We estimate the rigid fixation segment at roughly USD 150 million in 2024 within the USD 412 million total, growing faster than wire-based closure. Entrants that secure value analysis listings at the roughly 300 high-volume cardiac surgery programs in Texas, Florida, and Ohio can address most of the segment's demand without national distribution.

A second opportunity lies in resorbable closure devices for patients with elevated bleeding or infection risk, although reimbursement parity remains absent. Distributors offering bundled implant and instrument trays to community hospitals in the Southeast and Midwest can capture share from incumbents concentrated in large academic centers. Partnerships with contract sterile processing providers also create recurring revenue through reprocessing and inventory management contracts.

Market at a Glance

Leading Market Participants

• Ethicon (Johnson & Johnson)
• DePuy Synthes
• Zimmer Biomet
• Stryker
• Medtronic
• KLS Martin
• Smith & Nephew
• Integra LifeSciences
• B. Braun (Aesculap)
• Teleflex

Regulatory and Policy Environment

The Food and Drug Administration regulates sternal closure systems under the Federal Food, Drug, and Cosmetic Act, with 510(k) premarket notification as the primary pathway. Manufacturers must also meet the Quality Management System Regulation, which the FDA amended to incorporate ISO 13485 requirements, with the amended rule taking effect on February 2, 2026. Unique Device Identification labeling under 21 CFR Part 801 applies, and devices must be listed in the FDA Global Unique Device Identification Database.

The Centers for Medicare and Medicaid Services administers reimbursement through the Inpatient Prospective Payment System, where MS-DRG payments for cardiac surgery bundle implant costs. The New Technology Add-on Payment program can reimburse up to 65 percent of the cost of qualifying new devices above the DRG payment, subject to annual application and FDA clearance timing. Open Payments reporting under the Physician Payments Sunshine Act requires annual disclosure of manufacturer payments to surgeons, with CMS publishing the data each June.

Long-Term Outlook for Sternal Closure Systems in the U.S.

By 2032, the U.S. market is projected to reach USD 618 million, growing at a CAGR of 5.2 percent from the 2025 base year. Rigid fixation will capture a larger share of total value as the high-risk patient mix rises, while sternal wire volumes decline modestly in community hospitals. Growth will concentrate in institutions that document low dehiscence rates through Society of Thoracic Surgeons database participation.

Two forces will constrain this trajectory. Continued TAVR expansion into lower-risk patients will shrink open valve volume over the forecast period, and consolidation among hospital systems will strengthen GPO pricing leverage. Companies that build outcomes evidence and secure multi-year group contracts by 2028 will hold the most durable share.